At the European Hematology Association's 2026 congress, Ester in 't Groen, Therapeutic Area Head for Haematology at Johnson & Johnson Innovative Medicine EMEA, discussed the evolving treatment landscape for multiple myeloma.
In 't Groen highlighted the significant progress over the past two decades, noting that advances in T-cell redirecting therapies-particularly bispecific antibodies and CAR-T cell therapies-are extending survival for patients with relapsed disease.
The discussion focused on the shift toward earlier use of bispecifics, the potential of combination therapies, and the critical importance of personalized treatment strategies. She emphasized the rapid pace of innovation in haematology and the collective goal of developing more effective therapies to bring the elimination of cancer closer.
In 't Groen has held various leadership roles at Johnson & Johnson since 2011, with extensive experience in oncology and haematology strategy across the EMEA region.